Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports guideline-based hypercholesterolemia management for CHD prevention; extends prior consensus yet leaves optimal strategies open for prospective trials.
IN the past few years, physicians, the media, and the pharmaceutical industry have directed much attention to lowering the level of blood cholesterol to treat or prevent coronary heart disease. This awareness of hypercholesterolemia as a medical problem stems in part from the 1985 statement of the National Institutes of Health Consensus Development Conference entitled "Lowering Blood Cholesterol to Prevent Heart Disease,"1 and has been further reinforced by the National Cholesterol Education Program2 and the Surgeon General's Report on Nutrition and Health.3 The impetus for the statements comes principally from the results of the Lipid Research Clinics Coronary Primary Prevention . . .
No takes yet. Share an insight, caveat, or question.
Alexander Leaf (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: